Fused tricyclic compounds as inhibitors of tumor necrosis factor-α

US7964631B2 · kind B2 · utility

Assignee

• Piramal Life Sciences Limited · IN

Inventors

• Bansi Lal · Yellandu, IN
• Somesh Sharma · Los Altos, US
• Usha Ghosh · Mumbai, IN
• Swati Bal-Tembe · Mumbai, IN
• Tulsidas More · Mumbai, IN
• Pravin Gagare · West Lafayette, US
• Sunil Bhaginath Jadhav · Ahmednagar, IN
• Shashikant Patil · Mumbai, IN
• Asha Kulkarni-Almeida · Mumbai, IN
• Sapna Parikh · Mumbai, IN
• Radha Bhaskar Panicker · Jamkhed, IN
• Anagha Damre · Mumbai, IN
• Ravindra Dattatraya Gupte · Jamkhed, IN

Key dates

• Filing date: Aug 11, 2010
• Grant date: Jun 21, 2011
• Expiry date: Aug 11, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula 1:are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.